Key result
Percutaneous LAAC linked to a ~3% increase in mid-term MR-proANP serum levels.
Why the study?
Does percutaneous closure of the left atrial appendage alter cardiac biomarker levels (MR-proANP, NT-proBNP, hsTnI, hsTnT) in patients with non-valvular atrial fibrillation?
Observational (n=42)
Does percutaneous closure of the left atrial appendage alter cardiac biomarker levels (MR-proANP, NT-proBNP, hsTnI, hsTnT) in patients with non-valvular atrial fibrillation?
Percutaneous closure of the left atrial appendage significantly increases mid-term MR-proANP levels, suggesting an ongoing neuro-humoral effect of the device on the left atrial appendage.
LAA closure was associated with increased MR-proANP; leaves open neurohormonal relevance and need for prospective validation.
The left atrial appendage (LAA) represents both a predisposing source of thrombus formation and of neuro-humoral haemostasis. This study aims to evaluate changes of biomarker expression before and after successful percutaneous closure of the LAA. Patients with atrial fibrillation and contraindication for oral anticoagulant therapy were enrolled. Blood samples were taken within 24 hours before (T1) and at least 6 months (mid-term) (T2) after successful implantation of LAA occlusion devices. Blood levels of high sensitivity troponin I and T (hsTnI, hsTnT), aminoterminal pro-brain natriuretic peptide (NT-proBNP) and mid-regional pro-atrial natriuretic peptide (MR-proANP) were evaluated at both time points. A total of 42 patients with successful percutaneous LAA closure were included. Median mid-term follow-up was of 183 days. HsTnT, hsTnI and NT-proBNP did not show any significant differences over time. Serum levels of MR-proANP increased significantly between immediate pre-intervention (T1: median = 245.7 pmol/l, IQR 155.8-361.3 pmol/l) and at mid-term follow-up (T2: median = 254 pmol/l, IQR 183.4-396.4 pmol/l) (p = 0.037). These results indicate, that percutaneous LAA closure affects neuro-humoral haemostasis by increasing MR-proANP serum levels at mid-term follow-up.
No takes yet. Share an insight, caveat, or question.
Behnes et al. (2017) conducted an observational in Atrial fibrillation with contraindication for oral anticoagulant therapy (n=42). Percutaneous left atrial appendage (LAA) closure vs. Pre-intervention baseline was evaluated on Changes in MR-proANP serum levels (p=0.037). Percutaneous left atrial appendage closure significantly increased median MR-proANP serum levels from 245.7 pmol/l at baseline to 254 pmol/l at mid-term follow-up (p=0.037).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: